Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic

被引:4
作者
Marshall, Helen [1 ,2 ]
McIntyre, Peter [3 ,4 ]
Roberton, Don [1 ,2 ]
Dinan, Leonie [1 ,2 ]
Hardt, Karin [5 ]
机构
[1] Univ Adelaide, Sch Paediat & Reprod Hlth, Adelaide, SA 5006, Australia
[2] Womens & Childrens Hosp, Paediat Trials Unit, Youth & Womens Hlth Serv, Adelaide, SA 5006, Australia
[3] Univ Sydney, Natl Ctr Immunisat Res & Surveillance, Sydney, NSW 2006, Australia
[4] Childrens Hosp Westmead, Westmead, NSW, Australia
[5] GlaxoSmithKline Biol, Rixensart, Belgium
关键词
Pediatric immunization; DTPa-HBV; Hib; Safety; Immunogenicity; INACTIVATED POLIOVIRUS; CONJUGATE VACCINES; SINGLE INJECTION; IMMUNE MEMORY; IPV VACCINE; INFANTS; REACTOGENICITY; RESPONSES; DIFFICULTIES; PERSISTENCE;
D O I
10.1016/j.ijid.2009.03.004
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: The aim of this study was to evaluate the safety and immunogenicity of DTPa-HBV and Hib vaccines given mixed or separately to 360 healthy infants at 2, 4, and 6 months of age. Methods: Immune memory was assessed in lower responders (post-primary anti-PRP < 0.545 mu g/ml), through administration of plain polyribosylribitol phosphate (PRP) at 12-15 months. All subjects received a DTPa-HBV/Hib booster at 18-19 months. Results: One month after primary vaccination, 98% had seroprotective antibody levels against HBV and 94-97% against Hib (anti-PRP >= 0.15 mu g/ml). A statistically significant difference between groups was observed in the proportion of subjects who achieved anti-PRP antibodies >= 1.0 mu g/ml post-primary vaccination; 68.1% for DTPa-HBV/Hib and 84.5% for DTPa-HBV and Hib. PRP administered to lower responders produced a 7-fold increase in anti-PRP antibodies, indicative of immunological memory. After DTPa-HBV/Hib booster vaccination, 96-100% of subjects had seroprotective antibody concentrations against Hib, hepatitis B, tetanus, and diphtheria and high vaccine response rates against pertussis toxoid, filamentous hemagglutinin, and pertactin. Conclusion: A robust and protective Hib response was demonstrated following plain PRP and/or a booster conjugate Hib vaccine in both lower and higher Hib responders. (C) 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:E41 / E49
页数:9
相关论文
共 33 条